From masks and distancing to vaccines and therapeutics, federal pronouncements and actions have confidently rebuffed contrary evidence before sometimes — quietly — coming around.
The U.S. Food and Drug Administration (FDA) today authorized a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11, without convening its vaccine advisory panel of independent experts to discuss Pfizer’s data on 5- to 11-year-olds — and based on a study subset of only 67 children, CNBC reported.
The U.S. Food and Drug Administration (FDA) on Monday approved the use of the antiviral therapy, remdesivir, to treat COVID-19 in infants four weeks and older.
Heart inflammation requiring hospital care was more common among people who received COVID-19 vaccines than those who did not, according to a new study of tens of millions of Europeans.
The Joint Committee on Vaccination and Immunization (JCVI), an independent group of experts who advise the UK’s government health departments on immunizations published a report on 16 February stating, ‘JCVI advises a non-urgent offer at two 10mcg doses of the Pfizer-BioNTech Covid-19 vaccine to children aged 5 to 11 years of age who are not in a clinical risk group.’
Heart inflammation following COVID-19 vaccination was higher than expected in multiple age groups and was particularly pronounced in young men, according to a new data analysis from Centers for Disease Control and Prevention (CDC) researchers.
As of Sept. 27, 2021 there were 569,294 adverse event reports associated with COVID-19 vaccination in the U.S., according to the federal Vaccine Adverse Event Reporting System (VAERS).
